Bristol-Myers Squibb Q1 2025: Revenues Drop Despite Earnings Turnaround and Cost Reductions

Bristol-Myers Squibb Company (NYSE: BMY) has recently released its quarterly report for the period ending March 31, 2025. Below are key highlights and takeaways, reflecting both positive and negative aspects of the company's income statement.

• Total Revenues: $11.201 billion, a decrease of 5.6% from $11.865 billion in Q1 2024.
• Net Product Sales: $10.886 billion, down 5.8% from $11.559 billion year-over-year.
• Alliance and Other Revenues: $315 million, a slight increase from $306 million in the previous year.
• Cost of Products Sold: Increased to $3.033 billion from $2.932 billion.
• Selling, General and Administrative Expenses: Dropped sharply to $1.584 billion from $2.367 billion, a 33% reduction.
• Research and Development Expenses: Reduced to $2.257 billion from $2.695 billion, reflecting a 16% decline.
• Acquired IPRD Expenses: Decreased dramatically to $188 million from $12.949 billion, indicating significant one-off costs in the prior year associated with acquisitions.
• Net Earnings: Reported at $2.462 billion compared to a loss of $11.908 billion in 2024.
• Earnings Per Share (EPS): Basic EPS rose to $1.21 from a negative $(5.89) in the previous year.
• Gross-to-Net (GTN) Adjustments: Increased overall to 45% of gross sales, leading to $8.988 billion in adjustments in Q1 2025.

Positive Aspects:

• Strong recovery in net earnings with a significant profit turnaround from Q1 2024.
• Substantial reduction in expenses, particularly in selling, general and administrative costs.
• Continued demand growth in the Growth Portfolio, reflected in product performance for drugs like Opdivo, Reblozyl, and Breyanzi, with revenue increases noted.
• Approval of various key products, enhancing the company’s market position, including recent FDA approvals for Opdivo and Camzyos.

Negative Aspects:

• Overall revenue decline encountered due to generic competition impacting sales specifically in the Legacy Portfolio products such as Revlimid and Pomalyst.
• Ongoing pressures from the redesign of the Medicare Part D program, particularly affecting key products like Eliquis.
• Research and development expenditures, although decreased, still reflect ongoing pressures to maintain an innovative pipeline amidst legislative changes.
• Legal proceedings and potential restructuring costs hint at possible future liabilities, particularly concerning ongoing litigation and acquisitions.

The current environment remains challenging as Bristol-Myers Squibb navigates changes to pricing regulations and generic competition. However, strategic actions in product approvals may help solidify growth despite current headwinds.